NeurologyLive® Year in Review 2024: Most-Listened Podcast Episodes

Author(s):

Key Takeaways

New McDonald criteria for multiple sclerosis emphasize early diagnosis and incorporate biomarkers like central vein sign and paramagnetic rim lesions.
Alzheimer drug development faces challenges with aducanumab discontinuation, while lecanemab and donanemab show potential and limitations.
Mivelsiran, an RNA interference therapeutic, shows promise in Alzheimer disease, with positive phase 1 study data on efficacy and safety.
The phase 3 PHOENIX study of AMX0035 in ALS highlights drug development lessons and potential applications in other neurologic conditions.
Vorasidenib, a mIDH 1/2 inhibitor, shows therapeutic benefits in neurocognition and seizure control for diffuse gliomas, with ongoing research addressing unmet needs.

As part of NeurologyLive®'s Year in Review, we've compiled the most-listened episodes of our biweekly podcast, Mind Moments®.

Throughout the course of the year, the NeurologyLive^® team put together nearly 30 episodes of our podcast, Mind Moments^®, which features quick, digestible interviews with experts on trending topics in clinical neurologic care. The podcast, which releases new episodes every other Friday (in addition to special episodes, on occasion), is available to listen across most major podcast platforms.

Here, we'll highlight just some of the most-listened episodes on NeurologyLive^® this year. Click the buttons to check out more of these conversations, and be sure to subscribe to our show to never miss an episode! Click here to subscribe to the Mind Moments podcast. Be sure to leave a rating and review for the show.

Hoping to listen on your favorite podcast app? See below:

1. Episode 125: Understanding Major Changes to New McDonald Criteria for Multiple Sclerosis

In this episode, Daniel Ontaneda, MD, PhD, a staff member of the Cleveland Clinic Mellen Center for Multiple Sclerosis, provided an in-depth overview on the new McDonald criteria to diagnose multiple sclerosis (MS), which was presented at the 40th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS).

EPISODE BREAKDOWN

1:10 – Focus and direction of new diagnostic criteria
3:00 – Overviewing specific changes to McDonald criteria
10:50 – Approach to diagnosing pre-MS; treating radiologically isolated syndrome earlier
12:55 – Neurology News Minute
15:10 – Incorporation of new biomarkers, central vein sign, paramagnetic rim lesions, OCT
21:45 – Unanswered questions/challenges left out of the diagnostic criteria

2. Episode 113: Lessons Learned in Alzheimer Drug Development

In this episode, Ian Kremer, executive director of the leaders Engaged on Alzheimer's Disease (LEAD) coalition, spoke several relevant topics regarding Alzheimer care as new novel therapeutics emerge. He talked about the lessons learned from the recent discontinuation of aducanumab (Aduhelm; Biogen), and the potential and limitations lecanemab (Leqembi; Eisai) and donanemab (Eli Lilly) may bring.

EPISODE BREAKDOWN

1:10 – Promise in the Alzheimer field in 2024
4:05 – Ways of improving efficiencies with drug develpment
9:10 – Discontinuation of aducanumab
11:10– Neurology News Minute
13:50 – Lessons learned from aducanumab, antiamyloid therapies
22:10– Conversations between clinicians and patients surrounding expectations/limitations of antiamyloid therapies and available treatments

3. Episode 122: RNA Therapeutics, Mivelsiran, and Treating Alzheimer Disease

In this episode, Sharon Cohen, MD, a behavioral neurologist, sat down to discuss positive data from an ongoing phase 1 study of mivelsiran (Alnylam Pharmaceuticals), the first investigational RNA interference therapeutic targeting amyloid precursor protein for Alzheimer disease (AD).

EPISODE BREAKDOWN

1:15 – Mechanism of action of mivelsiran and how it can be potentially beneficial in AD
4:15 – Growing knowledge of RNA therapeutics and their impact on neurologic conditions
7:00 – Neurology News Minute
10:10 – Phase 1 study data, including efficacy, safety, biomarker, and pharmacokinetic results
19:20 – How mivelsiran fits with other approved therapies for AD; future goals and directions of the drug

4. Episode 114: AMX0035, Phase 3 PHOENIX Study, and Amylyx's Future Drug Development

In this episode, Justin Klee and Josh Cohen, cofounders and cochief executive officers of Amylyx Pharmaceuticals, who sat down at the recently concluded AAN Annual Meeting to discuss the results from the pivotal phase 3 PHOENIX trial (NCT05021536) of AMX0035 (Relyvrio) in patients with amyotrophic lateral sclerosis (ALS).

EPISODE BREAKDOWN

1:05 – Decision behind removing AMX0035 from market
3:00 – Lessons from PHOENIX, AMX0035 drug development program
6:45 – Unraveling PHOENIX study data
10:00 – Neurology News Minute
12:10 – Potential of AMX0035 in other tauopathies, neurologic conditions
15:00 – Outlook of antisense oligonucleotide AMX0114 in ALS

5. Episode 116: Understanding Vorasidenib's Therapeutic Benefit on Neurocognition, Seizure Control in Diffuse Gliomas

In this episode, Katherine Peters, PhD, a neurologist and neurooncologist at the Preston Robert Tisch Brain Tumor Center at Duke University provided context on a new analysis from the phase 3 INDIGO trial, a study assessing vorasidenib in patients with mutant isocitrate dehydrogenase (mIDH) 1/2 diffuse gliomas.

EPISODE BREAKDOWN

1:05 – Mechanism of action of vorasidenib, a mIDH 1/2 inhibitor
2:00 – Overview of exploratory analysis results
4:20 – Significance of new data, how it adds to previous primary and secondary outcomes
5:50 – Neurology News Minute
8:25 – Next steps for the study and use of vorasidenib
10:35 – Remaining unmet needs for patients with diffuse gliomas